Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Pulmonx CorporationNASDAQ: LUNG

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $4.9M rose 3.0% year over year, behind the +8.4% change in trailing-twelve-month research & development. Sequentially, it rose 6.9% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Research & development amounted to 21.5% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.0% toward the trailing-twelve-month pace of +8.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.9M+6.9% QoQ
Last fiscal yearDec 2025
$19.49M+10.9% YoY
LTMMar 2026
$19.63M+8.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.0%——
1 year+10.9%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
19.49M USD
Year-over-year change
+10.9%
4-year CAGR
+10.5%

Research & Development vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's LTM Mar 2026 research & development of $19.63M is the 7th highest of the 10 companies compared; the peer median is $59.66M.
  • Its year-over-year change of +8.4% is the 3rd highest of 10, against a peer median of -5.4%.
  • Research & development amounts to 22.2% of revenue for LUNG, versus a peer median of 78.3%.
LUNG Competitors Peer median
Research & Development for LUNG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$200.25M +133.0%+35.5%78.3%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M +8.5%+10.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
LUNGPulmonx CorporationLTM Mar 2026$19.63M +8.4%+8.2%22.2%
HYPRHyperfine, Inc.LTM Mar 2026$16.26M -26.0%-14.7%106.1%
TELATELA Bio, Inc.LTM Jun 2026$9.54M +8.0%+1.0%11.9%
ASRTAssertio Holdings, Inc.LTM Mar 2026$1.71M -51.6%—1.7%
Peer median (excluding LUNG) $59.66M-5.4%+7.7%78.3%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.42M53.66M68.68M83.79M90.5M
Cost of Revenue12.79M13.8M17.92M21.79M23.36M
Gross Profit35.63M39.87M50.75M62M67.14M
Gross Margin73.6%74.3%73.9%74.0%74.2%
Research & Development13.06M15.4M18.08M17.57M19.49M
Selling, General & Admin69.87M83.11M94.61M102.14M101.31M
Operating Expenses82.93M98.5M112.69M119.71M120.8M
Depreciation & Amortization867K1.51M1.95M1.59M1.05M
EBITDA(46.62M)(55.99M)(55.09M)(50.79M)(49.17M)
EBITDA Margin-96.3%-104.3%-80.2%-60.6%-54.3%
Operating Income(47.3M)(58.64M)(61.94M)(57.7M)(53.66M)
Operating Margin-97.7%-109.3%-90.2%-68.9%-59.3%
Interest Income400K1.53M5.57M5.06M2.65M
Interest Expense829K1.07M3.23M3.51M3.16M
Other Income / Expenses(1.01M)67K1.66M1.81M286K
Income Before Tax(48.32M)(58.57M)(60.27M)(55.89M)(53.38M)
Pre-Tax Margin-99.8%-109.1%-87.8%-66.7%-59.0%
Income Tax Expense343K353K571K500K626K
Net Income(48.66M)(58.92M)(60.84M)(56.39M)(54M)
Net Margin-100.5%-109.8%-88.6%-67.3%-59.7%
EPS (Basic)(1.35)(1.59)(1.60)(1.44)(1.33)
EPS (Diluted)(1.35)(1.59)(1.60)(1.44)(1.33)
Weighted Avg Shares36.13M37.1M37.97M39.11M40.69M
Weighted Avg Shares (Diluted)36.13M37.1M37.97M39.11M40.69M

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.